Aimmune Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$55.0M | −$50.1M | −$133.3M | −$81.5M | −$36.0M | −$11.1M |
| Net income | −$54.3M | −$49.5M | −$131.3M | −$80.8M | −$35.8M | −$11.1M |
| Total assets | $204.4M | $339.6M | $206.9M | $298.8M | $212.4M | $2.5M |
| Total liabilities | $100.3M | $40.6M | $29.1M | $12.8M | $6.1M | $1.9M |
| Equity | $104.0M | $298.9M | $177.8M | $286.0M | $206.3M | $671,000 |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 62.2M | 51.5M | 50.2M | 42.2M | 42.2M | 4.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- −52.2%
- Return on assets
- −26.6%
- Return on capital (ROCE)
- −35.1%
- Liabilities / assets
- 49.1%
- Debt / equity
- 0.96×
- Book value / share
- $1.67
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -9.02distress
- Accruals / assets
- 69.1%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 19, 2020
- Entered a material agreement · Regulation FD disclosureAug 31, 2020
- Results of operationsJul 30, 2020
- Shareholder voteMay 28, 2020
- Results of operationsMay 11, 2020
- Results of operationsFeb 27, 2020
- Entered a material agreement · New financial obligation · Unregistered equity sale · Amended charter or bylawsFeb 5, 2020
- Other material eventJan 31, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 16, 2021
- 15-12BOct 23, 2020
- 8-KOct 19, 2020
- 4FORM 4 SUBMISSIONOct 15, 2020
- EFFECTOct 14, 2020
- EFFECTOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.